T.TO 0.13ENB.TO 0.8BEP.UN.TO -1.15CP.TO 1.15VRT -19.67NVDA -7.33TSM -15.23JPM -6.1
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

27.72
-0.00 (0.00%)
as of Sep 14, 2026, 8:00:00 pm Market Open.
583 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconSep 14, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Pfizer Inc. (PFE) is perceived as a defensive stock with an attractive dividend yield around 6-7%, appealing to income-focused investors. However, many experts express concern about the company's growth potential following a reliance on COVID-19 vaccine revenues, which have receded. The consensus indicates that while PFE maintains a low valuation (PE around 8-10x), its growth is stagnant or uncertain due to impending patent expirations and the challenges associated with developing new blockbuster drugs. Moreover, there are worries that the ongoing focus on acquisitions may not lead to the anticipated revenue boosts. Despite these concerns, some analysts suggest PFE could still perform well for patient investors, especially as sector interest begins to build. Ultimately, the outlook remains cautious, with a preference noted for other stocks in the pharmaceutical sector that exhibit better growth trajectories.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
BUY

Pfizer Inc(PFE)

Mar 26, 2009
Made a good acquisition of Wyeth. Have created value in previous acquisitions. Cut the dividend while making the deal so the stock price fell. This made a lot of sense. The big issue is whether this will fill a hole in their product line. Reasonable dividend and very good balance sheet.
Photo of Paul Harris, CFAPaul Harris, CFA
No
Unlock Rating
$14.38

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
DON'T BUY

Pfizer Inc(PFE)

Mar 18, 2009
A former glory growth stock. A lot of healthcare products and there is the issue of aging in America but that is offset by many of their expensive premier drugs going generic. Just cut their dividends. Would prefer other pharmaceutical stocks.
Photo of David AbellaDavid Abella
No
Unlock Rating
$14.25

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Feb 24, 2009
(A Top Pick Feb 27/08. Down 40%.)
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$13.59

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Feb 13, 2009
Cut the dividend in order to preserve cash to make acquisitions even though their balance sheets is fortress like. Lipitor is coming off patent in a couple of years. Stock has been very disappointing. A "show me" stock.
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$14.58

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Feb 09, 2009
(Market Call Minute.) Just completing an acquisition.
Photo of Brett HrybBrett HrybUnlock Rating
$14.71

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Feb 06, 2009
At this price it is probably near a low. Made a big acquisition that is scaring everybody. Can't see a lot of downside from here.
Photo of Charles BobrinskoyCharles Bobrinskoy
No
Unlock Rating
$14.84

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Jan 30, 2009
Made a huge bet with their acquisition of Wyeth and the patents are running off. If it doesn't work out they are going to have some very difficult times.
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$14.58

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jan 27, 2009
(A Top Pick Jan 7/08. Down 28,2%.) Likes it for its valuation and its recent acquisition of Wyeth, which gets them into biotechnology and vaccines. Cheap on an earnings basis. Over 4% dividend. In a recession, drug stocks do relatively well. Stock has been oversold.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$15.82

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Dec 30, 2008
Currently, pharmaceutical stocks are outperforming the market. A good place to hide and to make some money. Yield of 7.2%. Lots of cash.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$17.75

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 16, 2008
His model price is $24.87, a 50% upside. $24 billion in cash.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$17.36

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Dec 15, 2008
Get Out! Sell. Not a fan of pharmaceuticals. Feels innovations will be in biotechnology not pharmaceuticals.
Photo of Matthew McCallMatthew McCall
No
Unlock Rating
$16.63

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TRADE

Pfizer Inc(PFE)

Dec 09, 2008
Manufactures of the drug lipidore (the most popular cholesterol drug) Their patent is running out in 2011 - 2012 and they are considering walking away and getting into cancer drugs.
Photo of Alan Kral , CFA, CICAlan Kral , CFA, CICUnlock Rating
$16.47

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Dec 01, 2008
Health care space, specifically drugs and bio pharmaceuticals is interesting but this is not one that he would Buy. Continue to have issues with drugs coming off of patents and relatively low revenue growth. Would prefer something like Gilead Sciences (GILD-Q) or a generic like Teva (TEVA-Q). This is an area where you should have some exposure.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$15.28

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Nov 14, 2008
High dividend yield. Cheap because people think there is not much in the pipeline. Lipitor will be going off patent so earnings will drop. Almost like a short-term bond in that you get cash flow from existing drugs that are pretty dependable but not much growth. Sold his holdings about 2 years ago because of lack of growth. Relatively safe but not a lot of upside.
Photo of Charles BobrinskoyCharles Bobrinskoy
No
Unlock Rating
$16.28

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Nov 12, 2008
Have a lot of cash and produce a lot of cash flow. Very high dividend. They cannot seem to get any catalyst for growth. A lot of competition from generic drug companies.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$15.83

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
Showing 496 to 510 of 890 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

TPZ.TO 0.13$12.73
KBL.TO 0.98$42.9
PPL.TO -0.14$66.12
AQN.TO 0.11$7.46
EMA.TO -0.02$68.17

Today's Top Picks

T.TO 0.13$12.73
ENB.TO 0.8$67.03
BEP.UN.T… -1.15$40.98
CP.TO 1.15$124.99
VRT -19.67$237.39

Popular Articles

Latest Sell Signals

CPX.TO 1.15$124.99
AVGO -17.27$344.72
APP 10.28$334.24
XRE.TO 0.05$15.73
ORCL -5.49$144.79

Most Recent Experts

Ryan Bushell

Ryan Bushell

Newhaven Asset Management

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like